Loading
This analysis showed that the type of KIT mutation predicts response to imatinib: tumours with exon 11 mutations responded in over 80 percent of cases, exon 9 mutations in under half, and tumours without a KIT or PDGFRA mutation rarely responded.
Mutation analysis of tumours from 127 patients with advanced GIST treated with imatinib in the phase 2 B2222 trial, correlating KIT and PDGFRA genotype with response and progression-free survival.
Partial response was 83.5 percent in KIT exon 11-mutant tumours, 47.8 percent in exon 9-mutant tumours and 0 percent in tumours without a detectable KIT or PDGFRA mutation, with corresponding differences in event-free survival.
Mutation testing is standard before imatinib in GIST: exon 11 tumours receive 400 mg, exon 9 tumours are dosed at 800 mg, and PDGFRA D842V tumours are given avapritinib instead.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares Imatinib, Journal of Clinical Oncology.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares Imatinib, Journal of Clinical Oncology.
Shares Imatinib, Journal of Clinical Oncology.
Shares Imatinib, Journal of Clinical Oncology.
Shares Michael C. Heinrich, KIT exon 11-mutant GIST, Imatinib.
Shares KIT exon 11-mutant GIST, Imatinib.